Skip to content

Drew M. Pardoll

Johns Hopkins University

4 papers in the Anchorcite directory, published between 2012 and 2017, cited 37,145 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine · 2012 · 12,793 citations

    BACKGROUND: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. METHODS: We enrolled patients with advanced melanoma,…

  2. PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine · 2015 · 9,526 citations

    BACKGROUND: Somatic mutations have the potential to encode "non-self" immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to immune checkpoint blockade. METHODS: We conducted a phase 2 study…

  3. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine · 2012 · 8,054 citations

    BACKGROUND: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system. Blockade of interactions between PD-1 and PD-L1 enhances…

  4. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience · 2017 · 6,772 citations

    The genomes of cancers deficient in mismatch repair contain exceptionally high numbers of somatic mutations. In a proof-of-concept study, we previously showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death…

Metadata from OpenAlex (CC0).